SPONSOR

AbbVie

Total Trials

Recruiting

Phases

Phase 1, Phase 2, Phase 1, Phase 2, Phase 3

Conditions studied: Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Micro Satellite Stable Colorectal Cancer Gastric/Esophageal Cancer High-Grade Serous Ovarian Cancer Pancreatic Cancer Triple Negative Breast Cancer Dry Eye Syndrome Systemic Lupus Erythematosus Multiple Myeloma

AbbVie is a US-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. The company built its early commercial foundation on adalimumab (Humira), which became the world's best-selling drug for over a decade, treating rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and other immune-mediated conditions. AbbVie's clinical research now spans immunology, oncology/hematology, aesthetics, neuroscience, and eye care — driven significantly by the 2020 acquisition of Allergan.

In hematology, AbbVie's venetoclax (Venclexta) — a BCL-2 inhibitor developed with Genentech/Roche — has established itself as a cornerstone therapy in chronic lymphocytic leukemia and acute myeloid leukemia, with ongoing trials exploring combinations with targeted agents, CAR-T cells, and bispecific antibodies. The immunology pipeline post-Humira biosimilar era is focused on next-generation IL-23 inhibitors (risankizumab/Skyrizi) and JAK inhibitors (upadacitinib/Rinvoq), both of which are in Phase 3 trials across new indications including giant cell arteritis and uveitis.

AbbVie's neuroscience program includes significant investment in migraine prevention (atogepant, ubrogepant) and Parkinson's disease (levodopa-carbidopa intestinal gel continuous infusion). The aesthetics division, inherited from Allergan, runs trials on neurotoxins and dermal fillers, representing a distinct category of interventional research. AbbVie conducts trials at academic and clinical research sites globally and maintains an open innovation model through partnerships with smaller biotechs.

Frequently Asked Questions — AbbVie

What is venetoclax and for which blood cancers is AbbVie testing it?

Venetoclax (Venclexta) is a first-in-class BCL-2 inhibitor that restores programmed cell death in cancer cells that have become resistant to apoptosis. It is FDA-approved in combination with rituximab for relapsed/refractory CLL, with obinutuzumab for previously untreated CLL/SLL, and with azacitidine or decitabine for newly diagnosed AML in patients 75 years or older who cannot tolerate intensive chemotherapy. AbbVie and Genentech are jointly running Phase 3 trials testing venetoclax in additional combinations — including with ibrutinib, acalabrutinib, and CAR-T therapies — and exploring its role in other hematologic malignancies including follicular lymphoma and mantle cell lymphoma.

What immunology conditions does AbbVie study beyond rheumatoid arthritis?

AbbVie's current immunology trials extend well beyond RA. Risankizumab (Skyrizi), an IL-23p19 inhibitor, is approved and under active study in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with trials now expanding to ankylosing spondylitis and other spondyloarthropathies. Upadacitinib (Rinvoq), a selective JAK1 inhibitor, is approved in RA, atopic dermatitis, PsA, AS, non-radiographic axSpA, and Crohn's, with Phase 3 trials in giant cell arteritis, uveitis, and systemic lupus underway. AbbVie also has early-stage programs in systemic sclerosis and alopecia areata.

How has the Allergan acquisition changed AbbVie's clinical trial activity?

The 2020 Allergan acquisition significantly diversified AbbVie's trial portfolio beyond immunology and oncology. Allergan brought approved products in eye care (dry eye disease treatments), central nervous system (buprenorphine, muscle relaxants), aesthetics (onabotulinumtoxinA/Botox, Juvederm fillers), and women's health. Post-acquisition, AbbVie runs trials extending Botox indications (including bladder dysfunction, chronic migraine, limb spasticity), investigational eye disease therapies, and next-generation aesthetic biologics. The neuroscience portfolio now also includes CGRP receptor antagonists for migraine (atogepant) and opioid dependence programs.

AbbVie

Frequently Asked Questions — AbbVie

Clinical Trials by AbbVie

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections